Latest Peplin news



news 

01-Feb-10

LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition read more

21-Dec-09

Positive Results for LEO Pharma's Phase III Actinic Keratosis Trials on the Face and Scalp read more

12-Nov-09

Letter to our CDI Holders read more


Clinical trials

For information regarding Peplin's PEP005 (ingenol mebutate) Gel clinical trial programme or to find a participating centre. Please refer to: www.clinicaltrials.gov and type "peplin" in the search box. Alternatively, key clinical trials are summarized below.

Current studies

Reference Development Phase Status Indication No. of Patients Additional information
PEP005-009 Phase 2a Ongoing sBCC 58 (est) See press release

Completed studies

Reference Development Phase Status Indication No. of Patients Additional information
REGION-Ib Phase 3 Completed January 2010  AK, Non-Head 200 See press release
REGION-IIa Phase 3 Completed December 2009  AK, Head 250 See press release
REGION-IIb Phase 3 Completed December 2009  AK, Head 250 See press release
REGION-I Phase 3 Completed May 2009 AK, Non-Head 250 See press release
PEP005-015 Phase 2b Completed March 2009  AK, Head 240  See press release
PEP005-007 Phase 2 Completed December 2007 AK, face or face and scalp 88 See press release
PEP005-006 Phase 2 Completed June 2007 AK, body and scalp 222 See press release
PEP005-022 Phase 2b Completed late 2008 AK extensor forearm 64 Open label safety study
PEP005-008 Phase 2 Completed March 2007 Cutaneous squamous cell carcinoma 25 See press release
PEP005-002 Phase 2a Completed July 2006 Safety in nodular basal cell carcinoma 58 See press release
PEP005-003 Phase 2a Completed April 2006 Safety in superficial basal cell carcinoma 60 See press release
PEP005-004 Phase 2a Completed February 2006 Safety in AK 22 See press release
PEP005-001 Phase 2a Completed November 2005 Safety in AK 63 See press release
PEP005-005 Phase 1 Completed October 2006 Safety study: sensitisating potential of PE0005 in healthy volunteers 238 There were no reactions greater than minimal erythema at any time during induction

For further information please contact us at info@peplin.com